Study Evaluating CCI-779 in Relapsing Multiple Sclerosis
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of long-term therapy with 3 dose levels of oral
CCI-779 administered to subjects with relapsing MS who completed study 3066A2-205-WW.